A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle
Ocular Therapeutix Soars Amid Frenzied Takeover Whispers: Is Amgen Eyeing a Biotech Gem?
FDA Delivers Crushing Blow to Outlook Therapeutics: Eye Drug Approval for Wet AMD Declined